Aripiprazol (APZ) is a partial agonist of dopamine D2 receptor, which is widely used to treat psychiatric diseases such as schizophrenia. Because its agonistic activity is weaker than intrinsic dopamine, both an inhibitory effect in excess dopamine and a stimulatory effect in dopamine depletion are expected. Lower expression of extrapyramidal syndrome is also expected because of its agonistic effect on 5-HT2A receptor, however the relationship of APZ to motor symptoms are not well characterized yet. Here we report the effect of APZ on motor deficits in two mouse models of Parkinson‘s disease (PD). In acutely and peripherally MPTP-intoxicated mice, APZ normalized both a prolonged duration of akinesia-like immobility in bar test and an increased walking time in beam-walking test. In hemi-PD mice injected with 6-OHDA into the right medial forebrain bundle, APZ improved motor deficits characterized by a spontaneously circling activity and an asymmetrical step of hind limbs. Moreover, APZ showed a significantly lower score of abnormal involuntary movements, which is an index of drug-induced dyskinesia, compared to levodopa when administered 21 days. From the aspect of low motor adverse effects, these results may provide rationale for the use of APZ for psychosis in PD patients, although careful clinical observation is still required.